Efthymios Deliargyris

CIK: 0001751617

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)3 (50.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CTSO

Cytosorbents Corp

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

CTSO
Cytosorbents Corp
Aug 8, 2025
Award(A)
Direct
70K shares-
CTSO
Cytosorbents Corp
Jan 17, 2025
In-the-Money(X)
Direct
16.2K shares at avg. $1.00$16K
CTSO
Cytosorbents Corp
Jan 17, 2025
Other(J)
Series A Right Warrants
Direct
16.2K shares-
CTSO
Cytosorbents Corp
Jan 17, 2025
Other(J)
Series B Right Warrants
Direct
16.2K shares-
CTSO
Cytosorbents Corp
Oct 4, 2024
Award(A)
Stock Option (Right to Buy)
Direct
100K shares-
CTSO
Cytosorbents Corp
Oct 4, 2024
Award(A)
Stock Option (Right to Buy)
Direct
50K shares-

		Type	Shares	Price		Ownership
Aug 8, 2025	CTSO Cytosorbents Corp	Award(A)	70,000	-	-	Direct
Jan 17, 2025	CTSO Cytosorbents Corp	In-the-Money(X)	16,233	$1.00	$16,233	Direct
Jan 17, 2025	CTSO Cytosorbents Corp	Other(J) Series A Right Warrants	16,233	-	-	Direct
Jan 17, 2025	CTSO Cytosorbents Corp	Other(J) Series B Right Warrants	16,233	-	-	Direct
Oct 4, 2024	CTSO Cytosorbents Corp	Award(A) Stock Option (Right to Buy)	100,000	-	-	Direct
Oct 4, 2024	CTSO Cytosorbents Corp	Award(A) Stock Option (Right to Buy)	50,000	-	-	Direct

1-6 of 6 transactions

About Deliargyris Efthymios

Deliargyris Efthymios (SEC CIK 0001751617) files insider reports with the SEC as Chief Medical Officer of Cytosorbents Corp (CTSO).

Signal8 holds 3 ownership filings by Deliargyris Efthymios, all Form 4s, filed between Oct 8, 2024 and Aug 8, 2025. Those filings report 6 transactions, from Oct 4, 2024 to Aug 8, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Deliargyris Efthymios's filings is in PRINCETON, NJ.

Recent filings by Deliargyris Efthymios

Aug 8, 2025: Grant or award of CTSO shares (Form 4, code A).
Jan 17, 2025: Option exercise of CTSO shares (Form 4, code X).
Jan 17, 2025: Other transactions of CTSO derivative securities (2 lines, Form 4, code J).
Oct 4, 2024: Grants or awards of CTSO derivative securities (2 lines, Form 4, code A).

Other insiders filing for Cytosorbents Corp (CTSO)

Chan Phillip P., Chief Executive Officer
Capponi Vincent, President and COO
Sobel Alan D., Director
MARIANI PETER J, Chief Financial Officer
Jones Edward Raymond, Director
BATOR MICHAEL G., Director

How to read Form 4 transaction codes